France· FR:62003633
BLINCYTO 38,5 microgrammes, poudre pour solution à diluer et solution pour solution pour perfusion
A medicinal product containing blinatumomab, registered in France by AMGEN EUROPE.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- BLINATUMOMAB
- Manufacturer
- AMGEN EUROPE
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
- cip1334009550134711 flacon(s) en verre - 1 flacon(s) en verre de 10 ml
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Blinatumomab in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandBlincytoParanova Oy
- NorwayBlincytoAbacus Medicine A/S
- SwitzerlandBlincyto
- CzechiaBLINCYTOAmgen Europe B.V., Breda
- SpainBlincyto 38,5mcg de polvo para concentrado y solucion para solucion para perfusionAmgen Europe B.V.
- United KingdomBlincyto 38.5micrograms powder for concentrate and solution for solution for infusion vialsAmgen Ltd
- IrelandBLINCYTO 38.5 micrograms powder for concentrate and solution for solution for infusionAmgen Europe B.V.,
- IcelandBlincytoAmgen Europe B.V.*
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Blincyto
- Norway · Blincyto
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ea0c361e-0f60-4238-9a4a-ea14d9dc766e GET /v1/drugs/ea0c361e-0f60-4238-9a4a-ea14d9dc766e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "62003633",
"date_amm": "2015-11-23",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/15/1047",
"substance": "BLINATUMOMAB",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "poudre à diluer à diluer et solution pour solution pour perfusion",
"voies_administration": "intraveineuse",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about blinatumomab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.